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 Abstract 
Context: Current evidence-based management for clinically localised prostate cancer includes 
active surveillance, surgery, external beam radiotherapy (EBRT) and brachytherapy. The 
impact of these treatment modalities on quality of life (QoL) is uncertain. 
Objective: To systematically review comparative studies investigating disease-specific QoL 
outcomes as assessed by validated cancer-specific Patient Reported Outcome Measures with 
at least 1 year of follow-up after primary treatment for clinically localised prostate cancer. 
Evidence acquisition: Medline, Embase, AMED, PsycINFO and the Cochrane Library were 
searched to identify relevant studies. Studies were critically appraised for risk of bias. A 
narrative synthesis was undertaken. 
Evidence synthesis: Of 11,486 articles identified, 18 studies were eligible for inclusion 
including 3 RCTs (follow-up range: 60-72 months) and 15 non-randomised comparative 
studies (follow-up range: 12-180 months) recruiting a total of 13,604 patients. Two RCTs 
recruited small cohorts and only one was judged as low risk of bias. The quality of evidence 
from observational studies was low to moderate. For a follow-up of up to six years, active 
surveillance was found to have the lowest impact on cancer-specific QoL, surgery had a 
negative impact on urinary and sexual function when compared to active surveillance and 
EBRT, while EBRT had a negative impact on bowel function when compared to active 
surveillance and surgery. Data from one small RCT reported that brachytherapy has a negative 
impact on urinary function 1 year post treatment, but no significant urinary toxicity were 
reported at 5 years. 
Conclusions: This is the first systematic review comparing the impact on cancer- specific QoL 
of different primary treatments for men with clinically localised PCa, using validated cancer-
specific PROMs only. There is robust evidence that choice of primary treatment for localised 
prostate cancer has distinct impacts on SDWLHQWV¶4R/7KLVVKRXOGEHGLVFXVVHGLQGHWDLOZLWK
patients during pre-treatment counselling. 
Patient Summary: Our review of the current evidence suggests that for a period of up to six 
years after treatment, men with localised prostate cancer who were managed with active 
surveillance reported high levels of QoL. Men treated with surgery reported mainly urinary 
and sexual problems, while men treated with external beam radiotherapy reported mainly 
bowel problems. Men eligible for brachytherapy reported urinary problems up to a year after 
therapy, but then their QoL returned gradually to as it was before treatment.  
 
 
 
 
 
 
 1. Introduction 
Since the introduction of PSA testing, there has been a substantial shift to a more favourable 
stage in newly-diagnosed prostate cancer (PCa), with approximately 81% of cases being 
diagnosed as clinically localised [1]. Currently, evidence-based management for clinically 
localised PCa includes active surveillance (AS), surgery, external beam radiotherapy (EBRT) 
and brachytherapy (BT) [2]. Knowledge of the adverse events of different management options 
is critical for making informed treatment decisions, considering that the survival benefit is 
uncertain, especially in men with favourable-risk PCa [3].  
The adverse effects of primary treatments for localised disease can negatively impact on 
disease-specific quality of life (QoL) [4]. The concept of 'quality of life' is subjective, however, 
in cancer cohorts, specific tools or Patient Reported Outcome Measures (PROMs) have been 
developed and validated. These questionnaires assess common issues that affect men after PCa 
diagnosis and treatment and generate scores, which reflect the impact on perceptions of health-
related quality of life (HRQoL). It is currently unclear which primary treatment for localised 
disease offers superior disease-specific QoL outcomes. The primary objective of this 
systematic review was to compare cancer-specific QoL data as measured by PROMs for 
intermediate (1-10 years) to long-term (>10 years) follow-up, among competitive treatments. 
 
2. Evidence acquisition 
2.1 Search strategy 
The review was performed according to Preferred Reporting Items for Systematic Reviews and 
Meta-analyses guidelines [5] and Cochrane review principles [6]. An experienced research 
librarian performed the search strategy in consultation with a multi-disciplinary panel of expert 
clinicians and patient representative (EAU Prostate cancer guideline panel). The database 
searched were EMBASE, MEDLINE, AMED, PsycINFO, Cochrane Database of Systematic 
Reviews, and Cochrane Central Register of Controlled Trials. Searches were limited to studies 
published from the year 2000 onwards. No language restrictions were imposed. Full details of 
the search strategies used are described in Appendix 1. 
All abstracts and full text articles were screened by two independent reviewers (MIL, MAL). 
Disagreement was resolved by discussion; if no agreement was reached, a third independent 
party acted as an arbiter (LB). 
2.2 Types of study design included 
Prospective randomised and non-randomised comparative studies with a sample size of at least 
10 patients per arm, reporting cancer-specific QoL outcomes measured by validated PROMs 
with at least 12 months of follow-up, were eligible for inclusion. 
2.3 Types of participants included 
The study population was aGXOWPHQ\HDUVRIDJHGLDJQRVHGZLWKFOLQically localised PCa 
(T1-T2c) that had not undergone any previous treatment prior to their primary treatment for 
PCa (with the exception of neoadjuvant Androgen Deprivation Therapy [ADT] preceding 
radiotherapy). 
2.4 Types of interventions included 
The following interventions were eligible for inclusion: 
(1) Active surveillance/monitoring (as defined by primary authors) 
(2) Radical prostatectomy (Open or Laparoscopic or Robot-Assisted) 
(3) Radiotherapy (3D conformal or Intensity Modulated [IMRT] or Stereotactic 
radiotherapy [SBRT]) +/- brachytherapy boost (Low Dose Rate [LDR] or High 
Dose Rate [HDR]); or Radiotherapy delivered with or without 
neoadjuvant/concurrent/adjuvant ADT for the treatment of localised PCa 
(4) Brachytherapy alone (LDR or HDR) 
 
Studies reporting comparisons between any of the above treatments were included. Studies 
reporting within treatment comparisons only (e.g. radiotherapy vs radiotherapy in combination 
with ADT) were excluded. 
2.5 Types of outcome measures included 
The primary outcome of this review was specified a priori and included cancer-specific QoL 
after primary cancer treatment, assessed by a validated PROM as defined by authors. In 
addition, a list of validated PROMs was used to identify potentially relevant studies and 
incorporated into the search strategy [7]. Studies using non-cancer specific PROMs or studies 
reporting cancer specific QoL using a non-validated tool were excluded, as were those studies 
reporting incomplete data from sub-domains of QoL PROMs. Secondary outcomes were sub-
domains of QoL PROMs related to PCa QoL e.g. sexual function, urinary function and bowel 
function. 
2.6 Assessment of risk of bias and confounding 
Randomised controlled trials (RCTs) risk of bias (RoB) assessment was undertaken using the 
recommended tool in the Cochrane Handbook for Systematic Reviews of Interventions [6].  
In non-randomised comparative studies (NRCSs), RoB was assessed using additional domains 
to assess the risk of confounders, which were developed a priori with clinical content experts 
(EAU Prostate Cancer Guideline Panel). This is a pragmatic approach informed by 
methodological literature pertaining to assessing RoB in NRCSs [8, 9]. The main confounding 
factors identified, included baseline QoL score, age, co-morbidities (any classification) and 
baseline Gleason score.  
2.7 Data analysis 
A data extraction form was developed a priori to collect information on study design, 
participant demographics, characteristics of interventions, and outcome measures. Two 
reviewers independently extracted data relating to the pre-specified outcomes. Descriptive 
statistics were used to summarise baseline characteristic data. For studies with more than two 
intervention groups, only the intervention groups relevant to the review were selected. If 
relevant data could be extracted and it was appropriate to do so, a meta-analysis of RCT data 
was planned. For studies with multiple publications, only the most up-to-date or complete data 
for each outcome was utilized. If meta-analyses of RCTs were inappropriate, a narrative 
synthesis of the evidence was performed. A narrative synthesis was undertaken for NRCSs 
[10]. 
 3. Evidence synthesis 
3.1 Quantity of evidence identified 
The study selection process is outlined in Figure 1. A total of 18 studies were eligible for 
inclusion: 3 RCTs [11-13] and 15 NRCSs [14-30] of which one NRCS [23, 24, 26] had multiple 
publications. Ultimately, a total of 13,604 patients were recruited (2,011 from RCTs and 11,593 
from NRCSs). 
 
3.2 Characteristics of the included studies 
Tables 1 and 2 present the baseline study characteristics for the 3 RCTs and 15 NRCSs, 
respectively. Due to heterogeneity of study PROMs data, a meta-analysis was not performed 
and consequently, data were summarised narratively instead. 
 
3.3 Risk of bias and quality assessment of the included studies 
Figures 2a and 2b present the RoB summary and confounder assessment for the three RCTs 
[11-13] and fifteen NRCSs [14-30]. As it was not possible to blind the participant to their 
intervention, all RCTs [11-13] had a high risk of bias for blinding of participants but we did 
not judge that this necessarily compromised study quality. One RCT [11] was also judged to 
have high selection bias (as only 19% of patients were randomly assigned to treatment arms), 
high bias due to closing prematurely and unclear detection bias, while another [13] was judged 
to have unclear selection and funding bias. 
The NRCSs had a high risk of selection, performance, and detection biases. The risks of 
reporting bias were low, while risks of attrition bias were moderate. All confounders were 
measured and corrected for, in five studies [17, 21, 26, 28, 30]. 
 
3.4 Comparisons of interventions results 
3.4.1. Data from RCTs 
Statistically significant differences, for QoL outcomes between or within treatment groups at 
the latest follow-up of each RCT [11-13] are shown in Table 3. The complete summary of the 
outcome results can be found in Supplementary Table 1.  
 
3.4.1.1 RP vs EBRT vs Active monitoring 
Data were obtained from the recently published study ProtecT trial [12], where 1643 men 
randomised to active monitoring, RP or EBRT. The trial predominantly enrolled men with low-
risk PCa. Trial retention and completion of follow-up assessments were higher than 85% for 
most outcome measures. Analyses were performed according to an intent-to-treat basis. 
Approximately 50% (291) of men who initially underwent active monitoring had either surgery 
or radiotherapy by the end of November 2015. 
Importantly, the study reported no difference in EORTC QLQ-C30 assessed global quality of 
life, up to 5 years of follow-up. However, Expanded Prostate Cancer Index Composite (EPIC) 
urinary summary scores were worse in men treated with RP compared to active monitoring or 
EBRT (88.7 vs 89.0 vs 91.4, respectively) as were urinary incontinence (80.9 vs 85.8 vs 89.4, 
respectively) and sexual summary, function and bother scores (32.3 vs 40.6 vs 41.3 for sexual 
summary, 23.7 vs 32.5 vs 32.7 for sexual function and 51.4 vs 57.9 vs 60.1 for sexual bother, 
respectively) at 6 years of follow-up. For men receiving EBRT, EPIC bowel scores deteriorated 
initially and although they improved after the first year, they were still poorer compared to 
active monitoring and RP at 6 years post-treatment in all domains: function (90.8 vs 92.3 vs 
92.3, respectively), bother (91.7 vs 94.2 vs 93.7, respectively) and summary (91.2 vs 93.2 vs 
93.0, respectively). 
 
3.4.1.2 RP vs BT 
For the comparison of RP vs BT, data were obtained from two RCTs. The SPIRIT trial [11] 
enrolled 168 men with low-risk PCa who received either RP or LDR BT. The investigators 
using the EPIC tool, found a statistically significant difference in the urinary and sexual 
domain, favouring men treated with LDR BT at a mean follow up of 5.2 years. These results 
should be interpreted with caution since only a minority of patients were randomly assigned to 
treatment arms (19%) and the trial was closed prematurely due to poor accrual. 
Another RCT [13] that recruited 200 patients with low-risk PCa, reported that urinary irritation 
was statistically significantly worse in the LDR BT arm when compared with pre-treatment 
values, while urinary incontinence was more common - although not statistically significantly 
different - in the nerve-sparing RP (NSRP) arm, at 1 year of follow up. However, there were 
no significant differences in EORTC-QLQ-C30/PR25 scores at 5 years of follow up. It is 
notable that only within group tests were reported in this trial.  
 
3.4.2. Data from NRCSs 
Statistically significant differences, for QoL outcomes between or within treatment groups at 
the latest follow-up of each NRCS [14-30] are shown in Table 4. The complete summary of 
the outcome results can be found in Supplementary Table 2. 
 
3.4.2.1 RP vs EBRT vs BT 
An observational study [25] compared men undergoing NSRP vs non-NSRP vs EBRT vs BT 
using the University of California, Los Angeles (UCLA) Prostate Cancer Index (PCI) tool. The 
study was characterised by poor participant retention at 5 and 10 years. However, at 2 years of 
follow-up (81% cohort retention), authors using NSRP as a reference value, reported that men 
treated EBRT were more likely to have a clinically significant decline [(CSD) at least half 
standard deviation from baseline] in bowel function and bother score, while men treated with 
BT were more likely to have a CSD in bowel bother score. Conversely, men were less likely 
to have a CSD in urinary and sexual function for BT and EBRT. These results are analogous 
with results from two other studies [14, 21]. The first [14] used the UCLA-PCI tool and for a 
follow up of up to five years reported that patients treated with EBRT had better sexual and 
urinary but worse bowel function than those treated with RP. BT patients had better sexual 
function, sexual bother and urinary function compared with RP patients, however, they had 
worse bowel function, bowel bother and urinary bother. The second study [21] assessed QoL 
scores at 3 years using the EPIC questionnaire. In comparison with NSRP, EBRT and BT 
caused significantly worse urinary irritative/obstructive adverse effects but less urinary 
incontinence and sexual dysfunction. EBRT also caused worse bowel and hormonal adverse 
effects. 
Sanda et al [27] using the EPIC tool, compared CSDs in QoL scores within treatment groups 
only, from baseline to 2 years post treatment. Patients in the RP group reported CSDs in urinary 
continence and sexual function, however urinary irritation/obstruction scores significantly 
improved after surgery. EBRT was also associated with improvement in urinary 
irritation/obstruction scores but with reduced QoL related to bowel function and vitality. 
Patients treated with EBRT plus ADT also reported CSD in sexual function. Surprisingly, 
patients in the BT group reported significant reduction in all QoL subdomain scores except 
vitality. 
 
3.4.2.2 RP vs EBRT or AS 
Four studies [23, 24, 26, 28-30] reported QoL outcomes in men with localised PCa undergoing 
RP or EBRT, however in one [29], authors did not compare differences in QoL scores between 
treatments. In the most recent update of the Prostate Cancer Outcomes Study (PCOS) [26], the 
authors compared QoL scores at 2, 5 and 15 years after primary therapy. Although men 
undergoing RP had significantly higher rates of incontinence and erectile dysfunction and 
lower rates of bowel urgency at 2 and 5 years, these rates were similar to those in the EBRT 
group at 15 years. Barocas et al [30] using the EPIC questionnaire, reported that RP was 
associated with a greater decrease in sexual function and urinary incontinence than EBRT at 3 
years of follow up. No clinically meaningful differences existed in bowel function beyond 12 
months. The fourth study [28] had a limited follow up and reported that men who underwent 
RP experienced significant declines in urinary and sexual function when compared to EBRT. 
Regarding comparison of QoL outcomes between RP and AS,  Jeldres et al [17] in a cohort of 
patients with low-risk PCa reported similar results to ProtecT trial [12], as at 3 years of follow 
up, patients who underwent surgery had significantly poorer urinary, sexual function and 
sexual bother scores. 
 
3.4.2.3 BT vs RP or EBRT 
Four studies assessed QoL outcomes in patients with localised PCa after BT or RP [15, 18-20]. 
The investigators in two studies [18, 20] included a small number of patients with a limited 
follow up of 12 months and using the UCLA-PCI questionnaire, reported statistically worse 
sexual function for patients in the RP arm. Namiki et al [20] also reported significantly better 
urinary function scores for patients treated with BT. Another small study [15] reported that at 
12 months sexual function was impaired significantly in patients after non-NSRP but not after 
NSRP when compared to patients treated with BT. In the largest prospective study [19], authors 
compared patients treated with RP, brachytherapy and cryotherapy. Statistical comparison for 
QoL outcomes between RP and BT cannot be made (as cryotherapy is not included in this 
review), nevertheless at 3 years of follow up BT patients tended to have better sexual and 
urinary scores.  
Only 2 studies [16, 22] compared QoL after BT and EBRT using the EPIC questionnaire. 
Pinkawa et al [22] reported that BT was associated with statistically significantly higher urinary 
toxicity at 16 months. Evans et al [16] reported similar results, however SBRT was associated 
with lower bowel toxicity than BT at 2 years.  
 
3.5 Discussion 
3.5.1 Principal findings 
The current review synthesises the existing evidence regarding cancer-specific QoL outcomes, 
of competitive treatments for clinically localised PCa. QoL is an important endpoint in PCa 
treatment and recently the COMPACTERS Study group, which developed a core outcome set 
for trials of effectiveness, identified QoL as an outcome which should be measured in all 
clinical trials of localised PCa [31]. Outcomes were measured by PROMs and the three most 
mainly used among the included studies were: EPIC, UCLA-PCI and EORTC QLQ-C30. 
The ProtecT trial [12] provides level 1 evidence for the different effects of PCa treatments on 
disease-specific QoL. No difference was found among treatment modalities in global quality 
of life at 5 years. However, surgery had a negative effect on urinary continence and sexual 
function, EBRT was associated with a negative effect in bowel function which was more 
intense the first year after treatment, while active monitoring had the lowest impact on disease-
specific QoL at 6 years. The PCOS 5-year results [26], confirm that men who underwent RP 
had a higher prevalence of urinary incontinence and erectile dysfunction, while men treated 
with EBRT had a higher prevalence of bowel dysfunction. Results from ProtecT trial are also 
comparable with the findings of the PIVOT Trial [32] as authors reported that at 2 years, 
urinary incontinence and erectile dysfunction were significantly more common among men 
who were assigned to RP when compared to men managed with observation.  
Most other observational studies provide similar, consistent intermediate-term results for RP 
and EBRT. However, in a recently published study [30], investigators reported that although 
EBRT was associated with a negative effect in bowel function, the difference in bowel domain 
score was below the threshold for clinical significance 12 months after treatment. As 81% of 
patients in the EBRT arm of the study received IMRT, these data suggest that the risk of side 
effects in contemporary treatments may be slightly less. Another discrepancy noted, is that 
while some studies report worse declines in urinary function after surgery [14, 25, 28], others 
report that surgery resulted in more incontinence but less irritating/obstructive symptoms than 
EBRT [21, 27, 30]. This variation could be explained by the use of different PROMs. Studies 
reporting urinary function decline after RP use the UCLA-PCI tool which focuses primarily on 
urinary incontinence, while studies reporting less irritative/obstructive symptoms use the EPIC 
tool. EPIC addresses irritative and obstructive voiding symptoms and provides a more 
comprehensive assessment of urinary QoL [33]. Urinary irritation symptoms are sometimes 
said to be worse with EBRT, however, this was not confirmed by ProtecT trial [12].  
Regarding the effect of AS on QoL, as recently highlighted [34] there is a lack of data. We 
were able to identify only one NRCS [17] including patients undergoing AS, which similarly 
to ProtecT trial [12] reported no major perturbations to their cancer-specific QoL.  
With respect to BT cancer-specific QoL outcomes, the best available evidence come from one 
small RCT [13]. The authors compared post-treatment QoL scores for patients undergoing BT 
and NSRP with their baseline scores only (there is no comparison between groups available), 
and they reported that at 1 year, BT had a negative impact on urinary irritative symptomatology. 
This result is consistent among all observational studies that use the EPIC tool, which addresses 
irritative-obstructive symptomatology [16, 21, 22, 27]. Unexpectedly, authors also reported 
that both BT and NSRP had no significant impact on QoL 5 years after treatment. Conversely, 
the SPIRIT trial [11], which directly compared QoL outcomes for BT and RP found a 
statistically significant difference in favour of BT in the urinary and sexual domains. In that 
trial though, the small difference in the overall mean scores in the urinary domain may have 
questionable clinical significance.   
As only a small proportion of patients with early stage PCa progress to metastatic disease and 
die from cancer within 10±15 years [35], understanding the long term impact of treatment on 
disease-specific QoL is critical. This systematic review revealed an important knowledge gap 
in the evidence base, as we were able to identify only one NRCS [26] that reported QoL 
outcomes at a follow up of more than 10 years. Interestingly, data from the PCOS [26], showed 
that there were no significant differences in the adjusted odds of urinary incontinence, bowel 
dysfunction or erectile dysfunction between RP and EBRT at 15 years. PCOS provided two 
further important observations; firstly, at the end of follow up, the prevalence of erectile 
dysfunction was very hiJKLQERWK treatment arms and secondly patients had significant 
declines in sexual and urinary function over the duration of follow up. These observations have 
also been reported for patients undergoing RP and watchful waiting (WW), in the most recent 
publication of the SPCG-4 trial, regarding HRQoL outcomes [36], for a median follow up of 
12.2 years. While it would be difficult to determine whether these declines are the consequence 
of treatment, advancing age or both, data from PLCO Trial comparing a sample of screened 
PCa survivors to a sample of screened noncancer controls, suggested that these persistent 
symptoms were due to treatment [37].   
 
3.5.2 Strength and limitations of the review 
The strengths of this review are the systematic, transparent, and robust approach taken to 
examine the evidence base, including the use of Cochrane review methodology, RoB and 
confounding assessment and adherence to PRISMA guidelines. The clinical question was 
prioritised by a multidisciplinary panel of clinical experts, methodologists, and patient 
representatives (EAU Prostate Cancer Guideline Panel), and the work was undertaken as part 
of WKHSDQHO¶VFOLQLFDOSUactice guideline update for 2017. The inclusion criteria restricted the 
review to studies reporting data on cancer-specific QoL outcomes, measured by validated 
PROMs only. This approach ensured a comprehensive review of the literature, while 
maintaining methodological rigour. 
It is important for the authors of this review to acknowledge several limitations. The number 
of RCTs providing level 1 evidence is limited (i.e. three) two of which recruited small cohorts. 
The quality of the evidence obtained from observational studies is problematic in relation to 
high risk of selection, performance, and detection biases and the minority of the studies 
accounting for our a priori identified confounders. There is large methodological heterogeneity 
among studies (as different PROMS being used to measure the same outcome, along with 
outcomes being measured at different time points), as well as heterogeneity regarding outcome 
reporting. An additional limitation is the fact that treatment arms in many included studies 
differ from contemporary care (i.e IMRT), as newer interventional techniques, especially 
newer EBRT techniques, may result in a lower risk and severity of side effects.  
 
3.5.3 How does this systematic review compare with other systematic reviews? 
To our knowledge, this is the first systematic review comparing the impact on cancer- specific 
QoL of different primary treatments for men with clinically localised PCa, using outcomes 
measured by validated cancer-specific PROMs only. The most recent systematic review [38] 
including mostly single treatment cohorts, is over four years out of date (searches up to January 
2013) and highlighted the lack of sufficient quality data to make recommendations to patients 
about QoL outcomes. Similar were the results of two previous reviews, which concluded that 
there was a paucity of clinically important information from high-quality RCTs on this topic 
[39, 40]. In another review by Chou et al [41], that included not only HRQoL outcomes, the 
authors reported that RP was associated with increased risk for urinary incontinence and 
erectile dysfunction, while EBRT was associated with increased risk for erectile and bowel 
dysfunction when compared with WW. Our systematic review differs from others with regards 
to the methodology, the strict inclusion and exclusion criteria and the robust methods used to 
synthesise the evidence and analyse the data. These are the principal strengths of our study. 
 
4. Conclusion 
Based on currently available evidence, choice of primary treatments for clinically localised 
PCa have a distinct impact on cancer-specific QoL, for a period of up to 6 years following 
treatment. Men managed with AS have good overall QoL scores, which are comparable or 
better than those of patients undergoing radical treatments. Surgery has a more pronounced 
negative impact on urinary and sexual function when compared to AS and EBRT, while EBRT 
has a more pronounced negative impact on bowel function when compared to AS and RP. Data 
from one small RCT including patients with low-risk disease reported that brachytherapy has 
a negative impact on urinary function at 1 year, but there are no significant differences in 
cancer-specific QoL 5 years after treatment. The review findings support the assertion that AS 
provides a good alternative to radical treatments in patients in whom it is desirable to prioritise 
QoL outcomes. The findings provide a basis for informing patients and clinicians regarding the 
impact of radical treatments on QoL. 
   
 
 
 References 
[1] Newcomer LM, Stanford JL, Blumenstein BA, Brawer MK. Temporal trends in rates of prostate 
cancer: declining incidence of advanced stage disease, 1974 to 1994. J Urol. 1997;158:1427-30. 
[2] Mottet N, Bellmunt J, Briers E, Bolla M, Cornford P, De Santis M, et al. Guidelines on Prostate 
Cancer. Accessed 12/07/16 at https://uroweb.org/wp-content/uploads/EAU-Guidelines-Prostate-
Cancer-2016-1.pdf. 2016. 
[3] Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, et al. 10-Year Outcomes after 
Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. N Engl J Med. 2016;375:1415-
24. 
[4] Bourke L, Boorjian SA, Briganti A, Klotz L, Mucci L, Resnick MJ, et al. Survivorship and Improving 
Quality of Life in Men with Prostate Cancer. Eur Urol. 2015. 
[5] Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and 
meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097. 
[6] Higgins JPT, Green S, (Editors). Cochrane handbook for systematic reviews of interventions 
Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011. 
[7] Morris C, Gibbons E, Fitzpatrick R. A structured review of patient-reported outcome measures for 
men with prostate cancer. University of Oxford. Accessed 11/02/16 at 
http://phi.uhce.ox.ac.uk/pdf/CancerReviews/PROMs_Oxford_Prostate%20Cancer_012011.pdf. 
2009. 
[8] Deeks JJ, Dinnes J, D'Amico R, Sowden AJ, Sakarovitch C, Song F, et al. Evaluating non-randomised 
intervention studies. Health Technol Assess. 2003;7:iii-x, 1-173. 
[9] Reeves BR DJ, JHiggins JPT and Wells  GA on behalf of the Cochrane Non-Randomised Studies 
Methods Group.. Chapter 13 Including non-randomised studies. In Higgins JPT, Green S. Cochrane 
handbook for systematic reviews of interventions v.5.0.2. The Cochrane Collaboration, 2011. 
http://www.cochrane-handbook.org/. Accessed February 2016. 
[10] Popay J, Roberts H, Sowden A, Petticrew M, Arai L, Rodgers M, et al. Guidance on the conduct of 
narrative synthesis in systematic reviews: A product from the ESRC Methods Programme, version 1, 
2006. Lancaster: Institute of Health Research. 
[11] Crook JM, Gomez-Iturriaga A, Wallace K, Ma C, Fung S, Alibhai S, et al. Comparison of health-
related quality of life 5 years after SPIRIT: Surgical Prostatectomy Versus Interstitial Radiation 
Intervention Trial. J Clin Oncol. 2011;29:362-8. 
[12] Donovan JL, Hamdy FC, Lane JA, Mason M, Metcalfe C, Walsh E, et al. Patient-Reported 
Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med. 
2016;375:1425-37. 
[13] Giberti C, Chiono L, Gallo F, Schenone M, Gastaldi E. Radical retropubic prostatectomy versus 
brachytherapy for low-risk prostatic cancer: a prospective study. World J Urol. 2009;27:607-12. 
[14] Bacon C, Giovannucci E, Testa M, Kawachi I. The impact of cancer treatment on quality of life 
outcomes for patients with localized prostate cancer. J Urol. 2001;166:1804-10. 
[15] Borchers H, Kirschner-Hermanns R, Brehmer B, Tietze L, Reineke T, Pinkawa M, et al. Permanent 
125I-seed brachytherapy or radical prostatectomy: a prospective comparison considering 
oncological and quality of life results. BJU Int. 2004;94:805-11. 
[16] Evans JR, Zhao S, Daignault S, Sanda MG, Michalski J, Sandler HM, et al. Patient-reported quality 
of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and 
brachytherapy. Radiother Oncol. 2015;116:179-84. 
[17] Jeldres C, Cullen J, Hurwitz LM, Wolff EM, Levie KE, Odem-Davis K, et al. Prospective quality-of-
life outcomes for low-risk prostate cancer: Active surveillance versus radical prostatectomy. Cancer. 
2015;121:2465-73. 
[18] Kobuke M, Saika T, Nakanishi Y, Ebara S, Manabe D, Uesugi T, et al. Prospective longitudinal 
comparative study of health-related quality of life in patients treated with radical prostatectomy or 
permanent brachytherapy for prostate cancer. Acta Med Okayama. 2009;63:129-35. 
[19] Malcolm JB, Fabrizio MD, Barone BB, Given RW, Lance RS, Lynch DF, et al. Quality of life after 
open or robotic prostatectomy, cryoablation or brachytherapy for localized prostate cancer. J Urol. 
2010;183:1822-8. 
[20] Namiki S, Satoh T, Baba S, Ishiyama H, Hayakawa K, Saito S, et al. Quality of life after 
brachytherapy or radical prostatectomy for localized prostate cancer: a prospective longitudinal 
study. Urology. 2006;68:1230-6. 
[21] Pardo Y, Guedea F, Aguilo F, Fernandez P, Macias V, Marino A, et al. Quality-of-life impact of 
primary treatments for localized prostate cancer in patients without hormonal treatment. J Clin 
Oncol. 2010;28:4687-96. 
[22] Pinkawa M, Asadpour B, Piroth MD, Gagel B, Nussen S, Kehl M, et al. Health-related quality of 
life after permanent I-125 brachytherapy and conformal external beam radiotherapy for prostate 
cancer--a matched-pair comparison. Radiother Oncol. 2009;91:225-31. 
[23] Potosky AL, Davis WW, Hoffman RM, Stanford JL, Stephenson RA, Penson DF, et al. Five-year 
outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes 
study. J Natl Cancer Inst. 2004;96:1358-67. 
[24] Potosky AL, Legler J, Albertsen PC, Stanford JL, Gilliland FD, Hamilton AS, et al. Health outcomes 
after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes 
Study. J Natl Cancer Inst. 2000;92:1582-92. 
[25] Punnen S, Cowan JE, Chan JM, Carroll PR, Cooperberg MR. Long-term health-related quality of 
life after primary treatment for localized prostate cancer: results from the CaPSURE registry. Eur 
Urol. 2015;68:600-8. 
[26] Resnick MJ, Koyama T, Fan KH, Albertsen PC, Goodman M, Hamilton AS, et al. Long-term 
functional outcomes after treatment for localized prostate cancer. N Engl J Med. 2013;368:436-45. 
[27] Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, et al. Quality of life and 
satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358:1250-61. 
[28] Schapira MM, Lawrence WF, Katz DA, McAuliffe TL, Nattinger AB. Effect of treatment on quality 
of life among men with clinically localized prostate cancer. Med Care. 2001;39:243-53. 
[29] Symon Z, Daignault S, Symon R, Dunn RL, Sanda MG, Sandler HM. Measuring patients' 
expectations regarding health-related quality-of-life outcomes associated with prostate cancer 
surgery or radiotherapy. Urology. 2006;68:1224-9. 
[30] Barocas DA, Alvarez J, Resnick MJ, Koyama T, Hoffman KE, Tyson MD, et al. Association Between 
Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported 
Outcomes After 3 Years. JAMA. 2017;317:1126-40. 
[31] MacLennan S, Williamson PR, Bekema H, Campbell M, Ramsay C, N'Dow J, et al. A core outcome 
set for localised prostate cancer effectiveness trials. BJU Int. 2017. 
[32] Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, et al. Radical prostatectomy versus 
observation for localized prostate cancer. N Engl J Med. 2012;367:203-13. 
[33] Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the 
Expanded Prostate Cancer Index Composite (EPIC) for comprehensive assessment of health-related 
quality of life in men with prostate cancer. Urology. 2000;56:899ʹ905. 
[34] Bellardita L, Valdagni R, van den Bergh R, Randsdorp H, Repetto C, Venderbos LD, et al. How 
does active surveillance for prostate cancer affect quality of life? A systematic review. Eur Urol. 
2015;67:637-45. 
[35] Popiolek M, Rider JR, Andren O, Andersson SO, Holmberg L, Adami HO, et al. Natural history of 
early, localized prostate cancer: a final report from three decades of follow-up. Eur Urol. 
2013;63:428-35. 
[36] Johansson E, Steineck G, Holmberg L, Johansson J-E, Nyberg T, Ruutu M, et al. Long-term 
quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate 
Cancer Group-4 randomised trial. The Lancet Oncology. 2011;12:891-9. 
[37] Taylor KL, Luta G, Miller AB, Church TR, Kelly SP, Muenz LR, et al. Long-term disease-specific 
functioning among prostate cancer survivors and noncancer controls in the prostate, lung, 
colorectal, and ovarian cancer screening trial. J Clin Oncol. 2012;30:2768-75. 
[38] Whiting PF, Moore TH, Jameson CM, Davies P, Rowlands MA, Burke MA, et al. Symptomatic and 
quality of life outcomes following treatment for clinically localized prostate cancer: a systematic 
review. BJU Int. 2016. 
[39] Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL. Systematic review: 
Comparative effectiveness and harms of treatments for clinically localized prostate cancer. Annals of 
Internal Medicine. 2008;148:435-48. 
[40] Chen RC, Chang P, Vetter RJ, Lukka H, Stokes WA, Sanda MG, et al. Recommended patient-
reported core set of symptoms to measure in prostate cancer treatment trials. J Natl Cancer Inst. 
2014;106. 
[41] Chou R, Croswell JM, Dana T, et al. Screening for prostate cancer: A review of the evidence for 
the u.s. preventive services task force. Annals of Internal Medicine. 2011;155:762-71. 
 
